Jounce Therapeutics (NASDAQ:JNCE) is a biotech that should be on your radar in the coming weeks. That's because it is set to present new data from the ICONIC trial for its vopratelimab drug to treat patients with advanced solid tumors. This presentation will pretty much show why an RNA signature was selected to become a predictive biomarker for the potential of improved clinical outcomes in cancer patients. With such data on hand, there is an ability to initiate the phase 2 SELECT study in 2020 to use vopratelimab in combination with its other PD-1 inhibitor product known as JTX-4014. Besides this mid-stage SELECT study, there is another trial ongoing known as EMERGE. Both of these studies provide shots on goal for the monoclonal antibody of vopratelimab. A few catalysts in 2020 could help boost the value of the stock.
Why I believe that Jounce Therapeutics is a good speculative biotech is because of its approach to using a predictive RNA signature biomarker to potentially help increase clinical response rates in patients with certain types of cancer. I am taking the stance that future immunotherapy products are leaning more towards biomarker targeted drugs. That's why Jounce intends to initiate a phase 2 study with vopratelimab in mid-2020 known as SELECT. The basis of this study is that a predictive RNA signature biomarker will help choose only those patients who are to likely respond to treatment. I'm not bullish on this speculative biotech only because of the predictive biomarker approach being deployed in this study. It is also because along with the use of vopratelimab, Jounce intends to add into the mix its mid-stage ready PD-1 inhibitor asset known as JTX-4014. The data to be presented at the ASCO-SITC 2020 conference, taking place between February 6th through the 8th, will display the biomarker RNA signature of ICOS hi CD4 T-cells to be described below. Specifically, from the ICONIC study. What's the rational reason for deploying such a study? That's because in a prior phase 1 study, known as ICONIC, it was shown that patients were able to show a benefit against multiple measures when using vopratelimab alone or in combination with another PD-1 inhibitor known as Opdivo (nivolumab). Such positive measures observed were:
The main mechanism of action for vopratelimab (monoclonal antibody) is that it binds to T-cells and activates "Inducible T-cell Co-Stimulator", thus the name ICOS. ICOS is a protein that is found on the surface of certain T-cells. What's important to note, which is shown above, is that ICOS only activates what is known as ICOS hi CD4 T-cells. These ICOS hi CD4 T-cells are the predictive biomarker to be deployed for the SELECT study. This brings up another point in that vopratelimab only engages CD4 T-cells and not CD8 T-cells. Why is that important? That's because CD4 T-cells are known to elicit a more robust response, while CD8 T-cells are not as keen. One other fact is that CD4 T-cells are known as helper cells, and they stimulate other immune cells in the body. They offer an adaptive immune response in both helping suppress and/or regulate immune responses. The initiation of the phase 2 SELECT study will be an important milestone for Jounce, which I believe will be a catalyst for the stock. The presentation of biomarker data at the ASCO-SITC 2020 conference will act as another catalyst. The mid-stage SELECT study will be initiated in mid-2020. From there, interim results from this study won't be released until 2021.
There is another shot on goal with the use of vopratelimab. This is a phase 2 study known as EMERGENCE, which had already been initiated in June of 2019. What's different about the EMERGENCE study is that it doesn't include a biomarker like the phase 2 SELECT study noted above. In other words, this is more of a broad approach to treating patients with cancer. Having said that, it doesn't get away from the main mechanism of action of vopratelimab, which is inducing ICOS hi CD4 T-cells to kill cancer cells. This phase 2 EMERGENCE study is going to be using the combination of vopratelimab + Yervoy (ipilimumab). Wait a second, why the need for Yervoy to be incorporated into this study? That's because Yervoy is an anti-CTLA4 inhibitor. It attaches to cancer cells and inhibits the CTLA4 response, which in essence helps boost the immune response against target cancer cells. There is another item that Yervoy does which is crucial and lines up with the mechanism of action of vopratelimab. It also induces ICOS hi T-cells like vopratelimab. Thus, the two products together each have a goal in this study:
So Yervoy acts like the launcher of inducing ICOS hi, and then vopratelimab is responsible for increasing such activity and then letting it sustain for a longer period of time. I believe such a mechanism has the chance to exhibit a more sustained durable response for cancer patients. This phase 2 study is being tested in patients with non-small cell lung cancer (NSCLC) and urothelial cancer. It is expected that efficacy and biomarker data from the EMERGE study will be revealed by the 2nd half of 2020.
According to the 10-Q SEC Filing, Jounce Therapeutics had cash, cash equivalents and investments of $185.1 million as of September 30, 2019. The company believes that it will have a gross cash burn between $80 million and $95 million for 2020. The company believes it has enough cash on hand to fund its operations into the second half of 2021. In my opinion, this is just an estimate. I think that once it initiates the phase 2 SELECT study, along with possibly advancing other early-stage studies, it is possible that the gross cash burn rate could increase. Another possible scenario is that it may choose to raise cash after positive data is released. When a company's stock trades higher on the back of positive clinical data, biotechs tend to take advantage with an immediate cash raise.
While some good preliminary data came from the phase 1 ICONIC study using vopratelimab in solid tumors was achieved, it is important to note that it is still in early-stage studies. There is no guarantee that the biomarker data to be presented at the ASCO-SITC 2020 conference is going to be highly positive. If that's the case, then it could be a non-event type of a catalyst. The other phase 2 studies noted above, EMERGE and SELECT still have a way to go before data is released for either of those. As for the EMERGE study, clinical data is not expected until the second half of 2020. The SELECT study has yet to be initiated and is not expected to begin until mid-2020. This means that in the short-term, it's quite possible that the stock could trade lower until such data is revealed.
Jounce Therapeutics is looking to take a differentiated approach with the use of its monoclonal antibody vopratelimab. As I laid out above, both phase 2 studies shown above will have one thing in common. That is the mechanism of action of vopratelimab in being able to induce ICOS hi T-cell responses to improved multiple measures in patients with cancer. One approach is to use Yervoy in combination with vopratelimab to accomplish this task. The other approach in the SELECT study is the use of a biomarker (ICOS hi T-cell population to benefit from treatment) and the addition of Jounce's very own PD-1 inhibitor JTX-4014. I believe that Jounce Therapeutics has a good shot to increase clinical outcomes for several cancer patient populations. Thus, I view it as a good speculative buy.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Originally posted here:
Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System - Seeking Alpha
- Technion team discovers important adaptive strategy of the microbiome, impacting immune system - The Jerusalem Post - April 16th, 2024
- Targeting aging and age-related diseases with vaccines - Nature.com - April 16th, 2024
- Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic ... - Nature.com - April 16th, 2024
- After the Smoke Clears: Scars on the Immune System - The Scientist - April 16th, 2024
- Exercise and the Immune System: What's the Latest Research? - Technology Networks - April 16th, 2024
- Analysis of immune cell infiltration characteristics in severe acute pancreatitis through integrated bioinformatics ... - Nature.com - April 16th, 2024
- Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original ... - Nature.com - April 16th, 2024
- Harnessing the power of the body's own cells to defeat cancer - Press Publications Inc. - April 16th, 2024
- Best Life: Immunotherapy targets brain cancer - Action News 5 - April 16th, 2024
- Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review | Cell Death ... - Nature.com - April 16th, 2024
- New insights on B cells: Researchers explore building better antibodies and curbing autoimmune diseases - Medical Xpress - April 16th, 2024
- Immune cells' intense reaction to the coronavirus may lead to pneumonia - Science News Magazine - April 16th, 2024
- The telltale traces long Covid leaves in the blood - healthcare-in-europe.com - April 16th, 2024
- Overview of the Immune System - The Merck Manuals - March 18th, 2024
- SUNDAY Unraveling The Gut-Brain Connection: How Infant Gut Bacteria Shape Immune Resilience | TheHealthSit - TheHealthSite - March 18th, 2024
- Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics | npj Systems Biology and ... - Nature.com - March 18th, 2024
- Study unlocks the mystery of neonatal neutropenia in newborns - News-Medical.Net - March 18th, 2024
- Vertebral Subluxation and Systems Biology: An Integrative Review Exploring the Salutogenic Influence of Chiropractic ... - Cureus - March 18th, 2024
- A new strategy to attack aggressive brain cancer shrank tumors in two early tests - ABC News - March 18th, 2024
- Turning on the Bat Signal - The Scientist - March 18th, 2024
- Power Foods That Can Support Your Immune System - Videos from The Weather Channel - The Weather Channel - March 18th, 2024
- Report: Aggressive brain tumors respond to new, immune-focused therapy - UPI News - March 18th, 2024
- Designer immune-cell therapy could shrink deadly brain tumors, early trials show - Livescience.com - March 18th, 2024
- 20.2: Introduction to the Immune System - Biology LibreTexts - February 27th, 2024
- Can one shot of yoghurt really boost your immunity and gut health? - Daily Mail - February 27th, 2024
- New cancer therapy approved by FDA supercharges bodys immune system - The Washington Post - February 27th, 2024
- How bubonic plague rewired the human immune system - BBC.com - February 27th, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Participate in Our Study for $100; Open Slots This Week - University of Arkansas Newswire - February 27th, 2024
- Sexual dimorphism during integrative endocrine and immune responses to ionizing radiation in mice | Scientific Reports - Nature.com - February 27th, 2024
- Comprehensive pan-cancer analysis identifies the RNA-binding protein LRPPRC as a novel prognostic and immune ... - ScienceDirect.com - February 27th, 2024
- YOUR HEALTH: The HAMR fights cancer - WAFB - February 27th, 2024
- Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat - News-Medical.Net - February 27th, 2024
- How the powerhouse of the cell could be cancers Achilles heel - Freethink - February 27th, 2024
- Food is medicine: The science behind zinc and other supplements for immune health - Healio - February 27th, 2024
- Unleashing Our Immune Response to Quash Cancer - Medscape - February 27th, 2024
- Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 ... - Nature.com - February 27th, 2024
- Converging and evolving immuno-genomic routes toward immune escape in breast cancer - Nature.com - February 27th, 2024
- Sanjula Jain Urges a Comprehensive Approach in Address Alarming Rise in Cancer Cases Among Younger Populations - Managed Healthcare Executive - February 27th, 2024
- Cystic fibrosis breakthrough points to zinc as infection buster - New Atlas - February 27th, 2024
- Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIVworkshop ... - Nature.com - February 27th, 2024
- Is the 100-year old TB vaccine a new weapon against Alzheimers? - The Guardian - February 27th, 2024
- Immune system in the blood of Alzheimer's patients found to be epigenetically altered - News-Medical.Net - February 10th, 2024
- What impact does exercise have on your immune system? And how to stay well while cycling - BikeRadar - February 10th, 2024
- Had COVID recently? Here's what to know about how long immunity lasts, long COVID, and more - AAMC - February 10th, 2024
- Noor Momin harnesses the immune system to treat heart disease | Penn Today - Penn Today - February 10th, 2024
- Research reveals a process tumors use to induce immune suppressor cells and evade immunotherapy - Medical Xpress - February 10th, 2024
- Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure - Nature.com - February 10th, 2024
- Preventing severe allergic reactions with nanoparticles - National Institutes of Health (NIH) (.gov) - February 10th, 2024
- Sugary handshakes are how cells talk to each other understanding these name tags can clarify how the immune ... - The Conversation Indonesia - February 10th, 2024
- Scientists have identified an immune cell that can cause allergies - EL PAS USA - February 10th, 2024
- Sickle cell and the importance of the immune system - Punch Newspapers - February 10th, 2024
- Which cancers can be treated with immune checkpoint inhibitors? - MD Anderson Cancer Center - February 10th, 2024
- How does waste leave the brain? Washington University School of Medicine in St. Louis - Washington University School of Medicine in St. Louis - February 10th, 2024
- Healthy Kids: Give your immune system a boost to stay healthy this winter - nbc16.com - February 10th, 2024
- The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode ... - Cardiovascular Diabetology - February 10th, 2024
- Impact of Chronic Stress on Immune System and Depression | Health News - Medriva - February 10th, 2024
- I tried 'swamp soup,' the viral recipe that promises to boost your immune system - Yahoo News - February 10th, 2024
- Understanding Immune Checkpoint Inhibition Therapy: Challenges and Strategies - Medriva - February 10th, 2024
- One Simple Change May Dramatically Boost The Effect of COVID-19 Vaccines - ScienceAlert - February 10th, 2024
- The gut virome is associated with stress-induced changes in behaviour and immune responses in mice - Nature.com - February 10th, 2024
- Cancer vaccines are in the works to fight BRCA-linked gene mutations - The Philadelphia Inquirer - February 10th, 2024
- What are the organs of the immune system? - InformedHealth.org - NCBI ... - January 17th, 2024
- Novel insights into the immune response to bacterial T cell superantigens - Nature.com - January 17th, 2024
- FDA signs off on Takeda's HyQvia as maintenance therapy for CIDP - FiercePharma - January 17th, 2024
- CBDs Pobezinsky and Pobezinskaya Use Flow Cytometry to Determine How Tumor Cells Outwit the Bodys Immune ... - UMass News and Media Relations - January 17th, 2024
- Boosting. What To Do. - Science Based Medicine - January 17th, 2024
- Axelia Oncology takes its TLR2/6 agonist into the clinic to harness the innate immune system - BioWorld Online - January 17th, 2024
- Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to ... - Nature.com - January 17th, 2024
- Opinion | Thanks to mRNA, Future Drugs Will Be Easier and Faster to Make - Mississippi Free Press - January 17th, 2024
- Elon research team models the COVID immune response, one equation at a time - Today at Elon - January 17th, 2024
- Are plant-based meals good for your immune system? 4 things to know about improving your health this week. - Yahoo Life - January 17th, 2024
- Scientists Find Key To Potential Breast Cancer Prevention, Treatment | Newsroom - UNC Health and UNC School of Medicine - January 17th, 2024
- What if every germ hit you at the exact same time? An immunologist explains - The Conversation - January 17th, 2024
- Why Don't We Have a Staph Vaccine? - Healthnews.com - January 17th, 2024
- Best ways to improve your immune system - The Business Standard - January 17th, 2024
- Stanford University researchers think future pandemics could be prevented with universal vaccines - KGO-TV - January 17th, 2024
- Why you may feel depressed and anxious when you're ill and how to cope with it - The Conversation - January 17th, 2024
- New mechanism with potential to boost checkpoint-blocking cancer immunotherapies identified - Medical Xpress - January 17th, 2024
- Battling Bugs and Blues: The Interplay of Infection and Emotion - News-Medical.Net - January 17th, 2024